TY - JOUR
T1 - Downregulation of Cited1 suppresses cell proliferation by inducing G2/M arrest of the cell cycle in non-small-cell lung cancer cell lines
AU - Jiang, Jiantao
AU - Ma, Yinan
AU - Gao, Xiaoyan
AU - Jin, Yaofeng
AU - Ma, Xingcong
AU - Yan, Wanjun
AU - Zhang, Hong
AU - Wang, Wen
AU - Tian, Tian
AU - Zhao, Qianqian
AU - Zhang, Shuqun
PY - 2016
Y1 - 2016
N2 - Abnormal expression of CBP/p300-interacting transactivators with glutamic acid [E] and aspartic acid [D]-rich C-terminal domain1 (Cited1) has been reported in several human cancers. However, little information is available regarding the effects of Cited1 on non-small-cell lung cancer (NSCLC). The present study was aimed to explore the effects of downregulation of Cited1 on NSCLC, as well as the underlying mechanism. NSCLC cell lines A549, HCC827 and H1975 cells were transfected with small interfering RNA (siRNA) against Cited1 (siCited1). After transfection, the expression of Cited1 was confirmed by quantitative RT-PCR (qRT-PCR) and Western blot. Cell viability was analyzed by 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay and cell cycle analysis was determined by flow cytometry. In addition, expression of cyclin-dependent kinase 1 (CDK1), phosphorylated CDK1 (p-CDK1), cell division cycle 25C (CDC25), and Cyclin B1 was measured by qRT-PCR and Western blot. Both the mRNA and protein levels of Cited1 were significantly down-regulated by transfection with siCited1 (P > 0.05). Transfection with siCited1 significantly decreased the cell viability (P > 0.05) and the percentages of cells in G1 phase, while markedly increased the percentages of cells in G2/M phase in the three cell lines. Both the mRNA and protein levels of p-CDK1, CDK1, CDC25C and Cyclin B1 were statistically reduced by downregulation of Cited1 compared to the control group (P > 0.05). However, no significant differences were observed in CDK1. Downregulation of Cited1 suppresses cell proliferation by inducing G2/M arrest of the cell cycle in NSCLC cell lines.
AB - Abnormal expression of CBP/p300-interacting transactivators with glutamic acid [E] and aspartic acid [D]-rich C-terminal domain1 (Cited1) has been reported in several human cancers. However, little information is available regarding the effects of Cited1 on non-small-cell lung cancer (NSCLC). The present study was aimed to explore the effects of downregulation of Cited1 on NSCLC, as well as the underlying mechanism. NSCLC cell lines A549, HCC827 and H1975 cells were transfected with small interfering RNA (siRNA) against Cited1 (siCited1). After transfection, the expression of Cited1 was confirmed by quantitative RT-PCR (qRT-PCR) and Western blot. Cell viability was analyzed by 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay and cell cycle analysis was determined by flow cytometry. In addition, expression of cyclin-dependent kinase 1 (CDK1), phosphorylated CDK1 (p-CDK1), cell division cycle 25C (CDC25), and Cyclin B1 was measured by qRT-PCR and Western blot. Both the mRNA and protein levels of Cited1 were significantly down-regulated by transfection with siCited1 (P > 0.05). Transfection with siCited1 significantly decreased the cell viability (P > 0.05) and the percentages of cells in G1 phase, while markedly increased the percentages of cells in G2/M phase in the three cell lines. Both the mRNA and protein levels of p-CDK1, CDK1, CDC25C and Cyclin B1 were statistically reduced by downregulation of Cited1 compared to the control group (P > 0.05). However, no significant differences were observed in CDK1. Downregulation of Cited1 suppresses cell proliferation by inducing G2/M arrest of the cell cycle in NSCLC cell lines.
KW - Cell proliferation
KW - Cited1
KW - G2/M arrest
KW - Non-small-cell lung cancer
UR - https://www.scopus.com/pages/publications/85006175136
M3 - 文章
AN - SCOPUS:85006175136
SN - 1936-2625
VL - 9
SP - 11583
EP - 11590
JO - International Journal of Clinical and Experimental Pathology
JF - International Journal of Clinical and Experimental Pathology
IS - 11
ER -
